TL;DR
Tampa Bay hosts a growing biotech cluster centered on Moffitt Cancer Center (one of the largest US cancer centers), USF Health, and the broader Tampa Bay Life Sciences operator network. Cluster is oncology-led with strong cell therapy and immunotherapy operators. Insurance program shape follows standard clinical-stage architecture with Florida regulatory overlay - Florida Information Protection Act (FIPA) cyber exposure, FL Board of Pharmacy oversight, and Middle District securities posture.
Tampa biotech
Tampa biotech insurance - Moffitt Cancer Center, USF Health, Tampa Bay Life Sciences.
Tampa Bay has built a meaningful biotech cluster centered on Moffitt Cancer Center - one of the largest US comprehensive cancer centers - and the University of South Florida (USF) Health system. The cluster leans heavily into oncology, cell therapy, and immunotherapy operators, with insurance characteristics shaped by that subject matter focus.
Cluster characteristics
Oncology biotech and cell therapy dominate.
Moffitt Cancer Center contributes spinouts across CAR-T, TIL, and adoptive cell therapy. Insurance program needs clinical trial liability with FDA-mandated long-term follow-up registry coverage, products liability towers scaled to irreversible-intervention exposure, and IP/E&O for Moffitt tech transfer office licensing terms.
USF Health contributes broader clinical-stage spinouts across oncology, infectious disease, and neuroscience. Standard clinical-stage architecture with attention to USF Patents and Licensing office terms.
Tampa Bay Life Sciences network operators run lean insurance programs at early-stage, scaling at funding rounds.
Tampa biotech coverage review